(Q38042441)

27 August 2017

title

Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs (English)

1 reference

27 August 2017

1 reference

10

Lars-Åke Levin

0 references

Mia Wadelius

Mia Wadelius

15

0 references

Dyfrig A. Hughes

Dyfrig A Hughes

8

0 references

Julia C Stingl

Julia C Stingl

14

0 references

Ann K Daly

Ann K Daly

5

0 references

Munir Pirmohamed

Munir Pirmohamed

12

0 references

Elisabeth Haschke-Becher

7

Elisabeth Haschke-Becher

1 reference

27 August 2017

Talitha I Verhoef

1

1 reference

27 August 2017

William K Redekop

2

1 reference

27 August 2017

Rianne Mf van Schie

3

1 reference

27 August 2017

Samira Bayat

4

1 reference

27 August 2017

Mary Geitona

6

1 reference

27 August 2017

Farhad Kamali

9

1 reference

27 August 2017

Lars-Åke Levin

10

1 reference

27 August 2017

Vangelis G Manolopoulos

11

1 reference

27 August 2017

Uwe Siebert

13

1 reference

27 August 2017

Anthonius de Boer

16

1 reference

27 August 2017

Anke-Hilse Maitland-van der Zee

17

1 reference

27 August 2017

EU-PACT group

18

1 reference

27 August 2017

publication date

1 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

1405-1417

1 reference

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Factors affecting the maintenance dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Pharmacogenetics of oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Optimizing the efficacy and safety of oral anticoagulant therapy: high-quality dose management, anticoagulation clinics, and patient self-management

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

A multinational investigation of time and traveling costs in attending anticoagulation clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Self-monitoring of oral anticoagulation: does it work outside trial conditions?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Self management of oral anticoagulation: randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Bleeding risks of antithrombotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Atrial fibrillation: the cost of illness in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Anticoagulant treatment of patients with chronic atrial fibrillation in primary health care in Sweden--a retrospective study of incidence and quality in a registered population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Resource consumption and management associated with monitoring of warfarin treatment in primary health care in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Thrombomodulin as a marker for bleeding complications during warfarin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Monitoring therapy with anticoagulants in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Planning and monitoring of patients for electrical cardioversion for atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Risks of oral anticoagulant therapy with increasing age.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Risk of intracerebral hemorrhage associated with phenprocoumon exposure: a nested case-control study in a large population-based German database

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

The costs of care in atrial fibrillation and the effect of treatment modalities in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Future costs of stroke in the Netherlands: the impact of stroke services

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

In-hospital direct cost of acute ischemic and hemorrhagic stroke in Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Management patterns and health care use after intracerebral hemorrhage. a cost-of-illness study from a societal perspective in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

[Cost of disorders of the brain in Austria in the year 2004].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.124

21 January 2018

Identifiers

DOI

10.2217/PGS.12.124

1 reference

27 August 2017

1 reference